tbuckley/cabot-search huggingface dataset:
Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial
Authors: Valérie Vilgrain, Helena Pereira, Eric Assenat, Boris Guiu, Alina Diana Ilonca, Georges-Philippe Pageaux, Annie Sibert, Mohamed Bouattour, Rachida Lebtahi, Wassim Allaham, Hélène Barraud, Valérie Laurent, Elodie Mathias, Jean-Pierre Bronowicki, Jean-Pierre Tasu, Rémy Perdrisot, Christine Silvain, René Gerolami, Olivier Mundler, Jean-Francois Seitz, Vincent Vidal, Christophe Aubé, Frédéric Oberti, Olivier Couturier, Isabelle Brenot-Rossi, Jean-Luc Raoul, Anthony Sarran, Charlotte Costentin, Emmanuel Itti, Alain Luciani, René Adam, Maïté Lewin, Didier Samuel, Maxime Ronot, Aurelia Dinut, Laurent Castera, Gilles Chatellier, Eric Assenat, Elisabeth Delhom - Christol, Boris Guiu, Alina D Ilonca, Julie Lonjon, Georges-Philippe Pageaux, Mohamed Abdel-Rehim, Wassim Allaham, Mohamed Bouattour, Laurent Castera, Arnaud Dieudonné, Rachida Lebtahi, Maxime Ronot, Annie Sibert, Valérie Vilgrain, Hélène Barraud, Christophe Bazin, Jean-Pierre Bronowicki, Valérie Laurent, Elodie Mathias, Carine Chagneau-Derrode, Rémy Perdrisot, Christine Silvain, Jean-Pierre Tasu, Patrick Borentain, René Gerolami, Olivier Mundler, Jean-Francois Seitz, Vincent Vidal, Christophe Aubé, Antoine Bouvier, Olivier Couturier, Frédéric Oberti, Laurent Vervueren, Isabelle Brenot-Rossi, Jean-Luc Raoul, Anthony Sarran, Julia Chalaye, Charlotte Costentin, Emmanuel Itti, Hicham Kobeiter, Alain Luciani, René Adam, Maïté Lewin, Didier Samuel, Julien Edeline, Etienne Garin, Yan Rolland, Isabelle Archambeaud, Thomas Eugene, Eric Frampas, Christophe Cassinotto, Martine Guyot, Jean-Baptiste Hiriart, Bruno Lapuyade, Julien Vergniol, Philippe Bachellier, Julien Detour, Bernard Duclos, Michel Greget, Francois Habersetzer, Alessio Imperiale, Philippe Merle, Agnès Rode, Julie Morvan, Eric Nguyen-Khac, Thierry Yzet, Guillaume Baudin, Patrick Chevallier, Abakar Mahamat, Thierry Piche, Micheline Razzouk, Patrick Hillon, Romaric Loffroy, Michel Toubeau, Julie Vincent, Gabriele Barabino, Nadia Bouarioua, Muriel Cuilleron, Marie Ecochard, Nathalie Prevot-Bitot, Vincent Leroy, Julie Roux, Christian Sengel, Valérie Bourcier, Nathalie Ganne-Carrie, Olivier Seror, Sylvie Costo, Thông Dao, Jean-Pierre Pelage, Jérôme Dumortier, Francesco Giammarile, Pierre-Jean Valette, Nadia Ghazzar, Olivier Pellerin, Julien Taieb, Pierre Weinmann, Alexandra Heurgue-Berlot, Claude Marcus, Daniele Sommacale, Maria-Angéla Castilla-Lièvre, Sophie Maitre, Lysiane Marthey
Journal: The Lancet Oncology (2017)
CTLA-4+PD-1− Memory CD4+ T Cells Critically Contribute to Viral Persistence in Antiretroviral Therapy-Suppressed, SIV-Infected Rhesus Macaques
Authors: Colleen S. McGary, Claire Deleage, Justin Harper, Luca Micci, Susan P. Ribeiro, Sara Paganini, Leticia Kuri-Cervantes, Clarisse Benne, Emily S. Ryan, Robert Balderas, Sherrie Jean, Kirk Easley, Vincent Marconi, Guido Silvestri, Jacob D. Estes, Rafick-Pierre Sekaly, Mirko Paiardini
Journal: Immunity (2017)

Antiretroviral therapy (ART) suppresses viral replication in HIV-infected individuals but does not eliminate the reservoir of latently infected cells. Recent work identified PD-1+ follicular helper T (Tfh) cells as an important cellular compartment for viral persistence. Here, using ART-treated, SIV-infected rhesus macaques, we show that CTLA-4+PD-1− memory CD4+ T cells, which share phenotypic markers with regulatory T cells, were enriched in SIV DNA in blood, lymph nodes (LN), spleen, and gut, and contained replication-competent and infectious virus. In contrast to PD-1+ Tfh cells, SIV-enriched CTLA-4+PD-1− CD4+ T cells were found outside the B cell follicle of the LN, predicted the size of the persistent viral reservoir during ART, and significantly increased their contribution to the SIV reservoir with prolonged ART-mediated viral suppression. We have shown that CTLA-4+PD-1− memory CD4+ T cells are a previously unrecognized component of the SIV and HIV reservoir that should be therapeutically targeted for a functional HIV-1 cure.
Reference values for oxygen saturation from sea level to the highest human habitation in the Andes in acclimatised persons
Authors: Jose Rojas-Camayo, Christian Richard Mejia, David Callacondo, Jennifer A Dawson, Margarita Posso, Cesar Alberto Galvan, Nadia Davila-Arango, Erick Anibal Bravo, Viky Yanina Loescher, Magaly Milagros Padilla-Deza, Nora Rojas-Valero, Gary Velasquez-Chavez, Jose Clemente, Guisela Alva-Lozada, Angel Quispe-Mauricio, Silvana Bardalez, Rami Subhi
Journal: Thorax (2017)

Oxygen saturation, measured by pulse oximetry (SpO 2 ), is a vital clinical measure. Our descriptive, cross-sectional study describes SpO 2 measurements from 6289 healthy subjects from age 1 to 80 years at 15 locations from sea level up to the highest permanent human habitation. Oxygen saturation measurements are illustrated as percentiles. As altitude increased, SpO 2 decreased, especially at altitudes above 2500 m. The increase in altitude had a significant impact on SpO 2 measurements for all age groups. Our data provide a reference range for expected SpO 2 measurements in people from 1 to 80 years from sea level to the highest city in the world.
TCT-421 Prevalence and treatment patterns for in-stent restenosis: A single center report from the Duke Databank for Cardiovascular Disease
Authors: Jay Shavadia, Karen Chiswell, Roseann White, Leslie Stephens, Tanya Schikorr, Prajakta Bhounsule, Mitchell Krucoff
Journal: Journal of the American College of Cardiology (2017)
A new lead to NLRP3 inhibition
Authors: Mohamed Lamkanfi, Vishva M. Dixit
Journal: The Journal of Experimental Medicine (2017)

The discovery of a small molecule inhibitor that targets the inflammasome sensor NLRP3 offers a new path for the development of selective inflammasome blockers with potential therapeutic benefit in a wide range of human diseases (in this issue, see Jiang et al., https://doi.org/10.1084/jem.20171419).
TCT-316 Radiation Exposure to Interventional Echocardiographers and Interventional Cardiologists during Structural Heart Interventions – Impact of Shielding
Authors: Frank Corrigan, Jose Miguel Iturbe, Jessica Forcillo, Ronnie Ramadan, C. Jose Condado, Norihiko Kamioka, Vinod Thourani, Vasilis Babaliaros
Journal: Journal of the American College of Cardiology (2017)
Sustained Release Talazoparib Implants for Localized Treatment of <i>BRCA1</i>-deficient Breast Cancer
Authors: Jodi E. Belz, Rajiv Kumar, Paige Baldwin, Noelle Castilla Ojo, Ana S. Leal, Darlene B. Royce, Di Zhang, Anne L. van de Ven, Karen T. Liby, Srinivas Sridhar
Journal: Theranostics (2017)

Talazoparib, a potent PARP inhibitor, has shown promising clinical and pre-clinical activity by inducing synthetic lethality in cancers with germline Brca1/2 mutations. Conventional oral delivery of Talazoparib is associated with significant off-target effects, therefore we sought to develop new delivery systems in the form of an implant loaded with Talazoparib for localized, slow and sustained release of the drug at the tumor site in Brca1-deficient breast cancer. Poly(lactic-co-glycolic acid) (PLGA) implants (0.8 mm diameter) loaded with subclinical dose (25 or 50 µg) Talazoparib were fabricated and characterized. In vitro studies with Brca1-deficient W780 and W0069 breast cancer cells were conducted to test sensitivity to PARP inhibition. The in vivo therapeutic efficacy of Talazoparib implants was assessed following a one-time intratumoral injection in Brca1Co/Co;MMTV-Cre;p53+/- mice and compared to drug-free implants and oral gavage. Immunohistochemistry studies were performed on tumor sections using PCNA and γ-H2AX staining. Sustained release of Talazoparib was observed over 28 days in vitro. Mice treated with Talazoparib implants showed statistically significant tumor growth inhibition compared to those receiving drug-free implants or free Talazoparib orally. Talazoparib implants were well-tolerated at both drug doses and resulted in less weight loss than oral gavage. PARP inhibition in mice treated with Talazoparib implants significantly increased double-stranded DNA damage and decreased tumor cell proliferation as shown by PCNA and γ-H2AX staining as compared to controls. These results demonstrate that localized and sustained delivery of Talazoparib via implants has potential to provide superior treatment outcomes at sub-clinical doses with minimal toxicity in patients with BRCA1 deficient tumors.
Incidence and risk factors of interstitial lung disease (ILD) of head and neck cancer patients treated with Cetuximab
Authors: Kenji Nakano, Shinichiro Taira, Makiko Ono, Junichi Tomomatsu, Toru Sasaki, Wataru Shimbashi, Hirofumi Fukushima, Hiroyuki Yonekawa, Hiroki Mitani, Shunji Takahashi
Journal: Annals of Oncology (2017)
TCT-805 Angina frequency and quality of life after implantation of bioresorbable scaffold implantation in complex lesions
Authors: Mariusz Tomaniak, Cordula Felix, Jiang Ming Fam, Nicolas Van Mieghem, Evelyn Regar, Joost Daemen, Jeroen Wilschut, Peter P.T. De Jaegere, Felix Zijlstra, Yoshinobu Onuma, Roberto Diletti, Robert-Jan van Geuns
Journal: Journal of the American College of Cardiology (2017)
Major Histocompatibility Complex Class II Alleles Influence Induction of Pathogenic Antiphospholipid Antibodies in a Mouse Model of Thrombosis
Authors: Elizabeth Papalardo, Zurina Romay‐Penabad, Rohan Willis, Premkumar Christadoss, Ana Laura Carrera‐Marin, Elba Reyes‐Maldonado, Rajani Rudrangi, Silvana Alfieri‐Papalardo, Ethel Garcia‐Latorre, Miri Blank, Silvia Pierangeli, Allan R. Brasier, Emilio B. Gonzalez
Journal: Arthritis & Rheumatology (2017)

Objective Both environmental and genetic factors are important in the development of antiphospholipid antibodies (aPL) in patients with antiphospholipid syndrome (APS). Currently, the only available data on predisposing genetic factors have been obtained from epidemiologic studies, without mechanistic evidence. Therefore, we studied the influence of major histocompatibility complex (MHC) class II alleles on the production of aPL in a mouse model of APS. Methods Three groups of mice, MHC class II–deficient (MHCII −/− ) mice, MHCII −/− mice transgenic for human HLA–DQ6 (DQ6), DQ8, or DR4 alleles, and the corresponding wild‐type (WT) mouse strains were immunized; half were immunized with human β 2 ‐glycoprotein I (β 2 GPI), and the other half were immunized with control ovalbumin (OVA) protein. Thrombus formation in vivo, tissue factor activity in carotid and peritoneal macrophages, and serum levels of tumor necrosis factor (TNF), IgG anticardiolipin (aCL), antibodies, and anti‐OVA antibodies were determined. Results Immunization with β 2 GPI induced significant production of aCL and anti‐β 2 GPI in WT mice compared with control mice immunized with OVA ( P &lt; 0.001) but diminished aCL ( P &lt; 0.001) and anti‐β 2 GPI ( P = 0.016) production in MHCII −/− mice. Anti‐β 2 GPI production was fully restored in DQ6 and DQ8 mice, while levels of anti‐β 2 GPI in DR4 mice and aCL in all transgenic lines were only partially restored ( P &lt; 0.001 to P &lt; 0.046). Thrombus size in WT mice was twice that in MHCII −/− mice ( P &lt; 0.001) but similar to that in all transgenic lines. Carotid and peritoneal macrophage tissue factor levels decreased by &gt;50% in MHCII −/− mice compared with wild‐type B6 mice and were restored in DQ8 mice but not DR4 mice or DQ6 mice. TNF levels decreased 4‐fold in MHCII −/− mice ( P &lt; 0.001) and were not restored in transgenic mice. Conclusion Our mechanistic study is the first to show that MHC class II alleles influence not only quantitative aPL production but also the pathogenic capacity of induced aPL.
TCT-544 The impact of residual mitral regurgitation ≤1+ following MitraClip therapy on long-term outcome
Authors: Eike Tigges, Daniel Reichart, Daniel Kalbacher, Christina Thomas, Florian Deuschl, Niklas Schofer, Lenard Conradi, Johannes Schirmer, Hermann Reichenspurner, Ulrich Schäfer, Stefan Blankenberg, Edith Lubos
Journal: Journal of the American College of Cardiology (2017)
ALK is a therapeutic target for lethal sepsis
Authors: Ling Zeng, Rui Kang, Shan Zhu, Xiao Wang, Lizhi Cao, Haichao Wang, Timothy R. Billiar, Jianxin Jiang, Daolin Tang
Journal: Science Translational Medicine (2017)

FDA-approved ALK-inhibiting drugs protect mice against sepsis through attenuating STING signaling activation in innate immune cells.
Northern Irish GPs warn patients that workforce crisis may mean turning them away
Authors: Abi Rimmer
Journal: BMJ (2017)

Patients in Northern Ireland have been warned that they may be turned away by their GP over the winter months because of a severe shortage of doctors.

Tom Black, chair of the BMA’s general practitioners committee in Northern Ireland, has written an open letter warning the public about the state of primary care.

The news comes as a report by the Royal College of Surgeons said that the health service in Northern Ireland was failing patients who are waiting for planned treatment. It said that the overall patient waiting times from referral to treatment …
Abstract 17004: Five-coordinate H64Q Neuroglobin as a Ligand-trap Antidote for Carbon Monoxide Poisoning
Authors: Ling Wang, Ivan Azarov, Jason J Rose, Qinzi Xu, Xueyin N Huang, Andrea M Belanger, Ying Wang, Lanping Guo, Chen Liu, Kamil B Ucer, Charles F McTiernan, Christopher P O’Donnell, Sruti Shiva, Jesus Tejero, Daniel B Kim-Shapiro, Mark T Gladwin
Journal: Circulation (2016)

Background: Carbon monoxide (CO) poisoning is a leading cause of poisoning deaths worldwide, with no available antidotal therapy. Neuroglobin (Ngb) is a six-coordinate hemoprotein, with the heme ir...
Locoregional Confinement and Major Clinical Benefit of <sup>188</sup>Re-Loaded CXCR4-Targeted Nanocarriers in an Orthotopic Human to Mouse Model of Glioblastoma
Authors: Delphine Séhédic, Igor Chourpa, Clément Tétaud, Audrey Griveau, Claire Loussouarn, Sylvie Avril, Claire Legendre, Nicolas Lepareur, Didier Wion, François Hindré, François Davodeau, Emmanuel Garcion
Journal: Theranostics (2017)

come from teaching and research institutions in France or abroad, or from public or private research centers.L'archive ouverte pluridisciplinaire
Injection of nanoparticles into cloven-hoof animals: Asking for trouble
Authors: Tore Skotland
Journal: Theranostics (2017)

This article aims at alerting scientists working with nanoparticles or microparticles about the specific adverse reactions due to the intravascular pulmonary macrophages present in pigs and other cloven-hoof animals, but not in humans.The history of a 25-year old study of an ultrasound contrast agent is used to illustrate these differences.
Whole exome sequencing in 342 congenital cardiac left sided lesion cases reveals extensive genetic heterogeneity and complex inheritance patterns
Authors: Alexander H. Li, Neil A. Hanchard, Dieter Furthner, Susan Fernbach, Mahshid Azamian, Annarita Nicosia, Jill Rosenfeld, Donna Muzny, Lisa C. A. D’Alessandro, Shaine Morris, Shalini Jhangiani, Dhaval R. Parekh, Wayne J. Franklin, Mark Lewin, Jeffrey A. Towbin, Daniel J. Penny, Charles D. Fraser, James F. Martin, Christine Eng, James R. Lupski, Richard A. Gibbs, Eric Boerwinkle, John W. Belmont
Journal: Genome Medicine (2017)

Left-sided lesions (LSLs) account for an important fraction of severe congenital cardiovascular malformations (CVMs). The genetic contributions to LSLs are complex, and the mutations that cause these malformations span several diverse biological signaling pathways: TGFB, NOTCH, SHH, and more. Here, we use whole exome sequence data generated in 342 LSL cases to identify likely damaging variants in putative candidate CVM genes. Using a series of bioinformatics filters, we focused on genes harboring population-rare, putative loss-of-function (LOF), and predicted damaging variants in 1760 CVM candidate genes constructed a priori from the literature and model organism databases. Gene variants that were not observed in a comparably sequenced control dataset of 5492 samples without severe CVM were then subjected to targeted validation in cases and parents. Whole exome sequencing data from 4593 individuals referred for clinical sequencing were used to bolster evidence for the role of candidate genes in CVMs and LSLs. Our analyses revealed 28 candidate variants in 27 genes, including 17 genes not previously associated with a human CVM disorder, and revealed diverse patterns of inheritance among LOF carriers, including 9 confirmed de novo variants in both novel and newly described human CVM candidate genes (ACVR1, JARID2, NR2F2, PLRG1, SMURF1) as well as established syndromic CVM genes (KMT2D, NF1, TBX20, ZEB2). We also identified two genes (DNAH5, OFD1) with evidence of recessive and hemizygous inheritance patterns, respectively. Within our clinical cohort, we also observed heterozygous LOF variants in JARID2 and SMAD1 in individuals with cardiac phenotypes, and collectively, carriers of LOF variants in our candidate genes had a four times higher odds of having CVM (odds ratio = 4.0, 95% confidence interval 2.5–6.5). Our analytical strategy highlights the utility of bioinformatic resources, including human disease records and model organism phenotyping, in novel gene discovery for rare human disease. The results underscore the extensive genetic heterogeneity underlying non-syndromic LSLs, and posit potential novel candidate genes and complex modes of inheritance in this important group of birth defects.
Mesh campaigners are dismayed by minister’s blunder over NICE guidance
Authors: Zosia Kmietowicz
Journal: BMJ (2017)

Campaigners have said that they feel betrayed by a government minister who led them to believe that guidelines from the National Institute for Health and Care Excellence (NICE) for treating stress incontinence and pelvic organ prolapse would be published before the end of the year.

Jackie Doyle-Price, England’s social care minister, was speaking at the end of a debate on surgical mesh implants in the House of Commons on 18 October, at which MPs relayed stories about how their constituents had been left in pain and unable to work or look after their families, with broken relationships, ruined sex lives, and post-traumatic stress disorder, after being fitted with mesh implants for stress incontinence, vaginal prolapse, or hernia repair.

Doyle-Price rejected MPs’ calls for a public inquiry into the number of people harmed after surgery to fit mesh implants, saying that a ban on the use of mesh implants was unnecessary.

“With regard to the evidence, we expect to …
Systematic reviews: let's keep them trustworthy
Authors: I. Garcia-Doval, E.J. van Zuuren, F. Bath-Hextall, J.R. Ingram
Journal: British Journal of Dermatology (2017)

e d fo r p u blic a tio n.Cit a tio n fo r fin al p u blis h e d ve r sio n: G a r ci a-Dov al, I., v a n Z u u r e n , E.J., B a t h-H ex t all, F. a n d In g r a m , Joh n R. 2 0 1 7.
CC-122 Exhibits Greater Preclinical Activity in Mantle Cell Lymphoma Than Lenalidomide through a Combination of Direct Cell-Autonomous and Increased Antibody Dependent Cell-Mediated Cytotoxicity
Authors: Patrick R. Hagner, Hsiling Chiu, Michelle F. Waldman, Anke Klippel, Michael Pourdehnad, Anita K. Gandhi, Anjan Thakurta
Journal: Blood (2016)
TCT-374 Novel method to assess both the epicardial and microvascular domain using vascular conductance obtained from intracoronary pressure and flow velocity
Authors: Nina van der Hoeven, Guus de Waard, Alicia Quirós, Alfonso de Hoyos, Sukhjinder Nijjer, Tim van de Hoef, Ricardo Petraco, Roel Driessen, Hernan Mejia-Renteria, Martijn Meuwissen, Paul Knaapen, Jan Piek, Justin Davies, Niels van Royen, Javier Escaned
Journal: Journal of the American College of Cardiology (2017)
PF-00337210, a potent, selective and orally bioavailable small molecule inhibitor of VEGFR-2
Authors: Tami Marrone, Dana Hu-Lowe, Maren Grazzini, Min-Jean Yin, Jeffrey Chen, Max Hallin, Karin Amundson, Shinji Yamazaki, David Romero, Aileen McHarg, Eileen Blasi, Yufeng Hong, Eileen Tompkins, Cynthia Palmer, Judith Deal, Brion Murray, James Solowiej, Michele McTigue, John Wickersham, Steven Bender
Journal: Cancer Research (2007)

3992  PF-00337210 is a potent, selective, and orally bioavailable small molecule inhibitor of VEGFRs. It is an ATP-competitive compound that is selective for VEGFR-2 when biochemically profiled against >100 diverse tyrosine and serine-threonine kinases. PF-00337210 preferentially binds to the unactivated kinase (Ki=0.7 nM) relative to the fully phosphorylated form (Ki= 8.8 nM). Crystallographic evidence suggests that its selectivity is likely a result of its ability to bind to a DFG-out conformation of VEGFR-2. In the cell, PF-00337210 inhibits the autophosphorylation of human and murine VEGFR-2 with IC50s of 0.87 ± 0.11 nM and 0.83 ± 0.29 nM, respectively. In cell-based assays, the compound is less potent against other split kinase family members: KIT (9.6 ± 3.4 nM), CSF1-R (13 ± 3 nM), PDGFR-α (11 ± 1 nM) and PDGFR-β (29 ± 8 nM), and does not inhibit Flt-3 (IC50 >10 μM). It also demonstrates greater than 60 fold selectivity for VEGFR-2 versus FGFR-1 in a growth factor stimulated HUVEC survival assay. PF-00337210 shows low to moderate in vivo clearance in several preclinical species (13, 22 and 25 mL/min/kg in rats, dogs and monkeys, respectively). It has high oral bioavailability in rats (>80%) and moderate oral bioavailability in dogs (>30%). In preclinical tumor models, the compound shows dose-dependent anti-tumor efficacy that is associated with significant reduction of microvessel density and vascular permeability in the tumor. The pharmacologically efficacious concentration of PF-00337210 is estimated to be
pH-Responsive Aerobic Nanoparticles for Effective Photodynamic Therapy
Authors: Lingyue Shen, Yu Huang, Dong Chen, Feng Qiu, Chuan Ma, Xin Jin, Xinyuan Zhu, Guoyu Zhou, Zhiyuan Zhang
Journal: Theranostics (2017)

Rationale: Photodynamic therapy (PDT), an O 2 -dependent treatment for inhibition of cancer proliferation, suffers from the low therapeutic effect in clinical application due to the hypoxic microenvironment in tumor cells.Methods: To overcome this obstacle, a stimuli-responsive drug delivery system with O 2 self-sufficiency for effective PDT was developed.In this study, pH-responsive aerobic nanoparticles were prepared by the electrostatic interaction between the O 2 -evolving protein Catalase and Chitosan.Subsequently, the photosensitizer Chlorin e6 (Ce6) was encapsulated in the nanoparticles.Results: The nanoparticles exhibited high stability in aqueous medium and efficient cellular uptake by tumor cells facilitating their accumulation in tumors by enhanced permeability and retention (EPR) effect.In acidic environment, irradiation caused disassembly of the nanoparticles resulting in the quick release of Catalase and the photosensitizer with continuous formation of cytotoxic singlet oxygen ( 1 O 2 ) greatly enhancing the PDT efficacy in hypoxic tumor tissues both in vitro and in vivo biological studies.Conclusion: Due to the unique O 2 self-sufficiency, the nanoparticles, upon irradiation, exhibited higher anticancer activity than free Ce6 both in vitro and in vivo.Our work has identified a new pH-triggered strategy to overcome hypoxia for effective PDT against cancer cells.